The inevitable QSAR renaissance

QSAR approaches, including recent advances in 3D-QSAR, are advantageous during the lead optimization phase of drug discovery and complementary with bioinformatics and growing data accessibility. Hints for future QSAR practitioners are also offered.

[1]  Bernd Wendt,et al.  Toluidinesulfonamide hypoxia-induced factor 1 inhibitors: alleviating drug-drug interactions through use of PubChem data and comparative molecular field analysis guided synthesis. , 2011, Journal of medicinal chemistry.

[2]  Stephen R. Johnson,et al.  The Trouble with QSAR (or How I Learned To Stop Worrying and Embrace Fallacy) , 2008, J. Chem. Inf. Model..

[3]  T. Gelder,et al.  Therapeutic Drug Monitoring for Mycophenolic Acid Is Value for (Little) Money , 2011 .

[4]  Stefan H. Unger,et al.  Model building in structure-activity relations. Reexamination of adrenergic blocking activity of .beta.-halo-.beta.-arylalkylamines , 1973 .

[5]  D. E. Patterson,et al.  Crossvalidation, Bootstrapping, and Partial Least Squares Compared with Multiple Regression in Conventional QSAR Studies , 1988 .

[6]  John Manchester,et al.  SAMFA: Simplifying Molecular Description for 3D-QSAR , 2008, J. Chem. Inf. Model..

[7]  Arthur M. Doweyko,et al.  3D-QSAR illusions , 2004, J. Comput. Aided Mol. Des..

[8]  S. Free,et al.  A MATHEMATICAL CONTRIBUTION TO STRUCTURE-ACTIVITY STUDIES. , 1964, Journal of medicinal chemistry.

[9]  C E Berkoff,et al.  Substructural analysis. A novel approach to the problem of drug design. , 1974, Journal of medicinal chemistry.

[10]  Bernd Wendt,et al.  Pushing the boundaries of 3D-QSAR , 2007, J. Comput. Aided Mol. Des..

[11]  D R Abernethy,et al.  Integration of Diverse Data Sources for Prediction of Adverse Drug Events , 2011, Clinical pharmacology and therapeutics.

[12]  A. Tropsha,et al.  Beware of q2! , 2002, Journal of molecular graphics & modelling.

[13]  R. M. Muir,et al.  Correlation of Biological Activity of Phenoxyacetic Acids with Hammett Substituent Constants and Partition Coefficients , 1962, Nature.

[14]  Bernd Wendt,et al.  Quantitative Series Enrichment Analysis (QSEA): a novel procedure for 3D-QSAR analysis , 2008, J. Comput. Aided Mol. Des..

[15]  D. Hawkins,et al.  Analysis of a Large Structure‐Activity Data Set Using Recursive Partitioning , 1997 .

[16]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[17]  C. Hansch,et al.  p-σ-π Analysis. A Method for the Correlation of Biological Activity and Chemical Structure , 1964 .

[18]  Richard D. Cramer,et al.  Rethinking 3D-QSAR , 2010, J. Comput. Aided Mol. Des..

[19]  Gerald M. Maggiora,et al.  On Outliers and Activity Cliffs-Why QSAR Often Disappoints , 2006, J. Chem. Inf. Model..

[20]  Yvonne Martin.  Overview of Quantitative Drug Design , 2010 .

[21]  Brian B. Masek,et al.  Virtual Screening for R-Groups, including Predicted pIC50 Contributions, within Large Structural Databases, Using Topomer CoMFA , 2008, J. Chem. Inf. Model..

[22]  Barry L. Levinson,et al.  Quantitative Drug Design: A Critical Introduction , 1979, The Yale Journal of Biology and Medicine.

[23]  Christopher S. Foote,et al.  Chemistry of singlet oxygen. XVII. 1,4-Addition products from styrene derivatives , 1973 .

[24]  B. Kowalski,et al.  Pattern recognition. II. Linear and nonlinear methods for displaying chemical data , 1973 .

[25]  Richard D. Cramer,et al.  Chapter 31: Quantitative Drug Design , 1976 .

[26]  R. D. Clark,et al.  Taming the combinatorial centipede , 1997 .

[27]  Bernd Wendt,et al.  Capturing Structure-Activity Relationships from Chemogenomic Spaces , 2011, J. Chem. Inf. Model..

[28]  Gary Tresadern,et al.  Modeling approaches for ligand-based 3D similarity. , 2010, Future medicinal chemistry.

[29]  T Scior,et al.  How to recognize and workaround pitfalls in QSAR studies: a critical review. , 2009, Current medicinal chemistry.

[30]  J. Dearden,et al.  How not to develop a quantitative structure–activity or structure–property relationship (QSAR/QSPR) , 2009, SAR and QSAR in environmental research.

[31]  S. Wold,et al.  The Collinearity Problem in Linear Regression. The Partial Least Squares (PLS) Approach to Generalized Inverses , 1984 .

[32]  Yvonne C. Martin.  Why you should read Dr. Cramer’s perspective , 2011, J. Comput. Aided Mol. Des..

[33]  R. Cramer,et al.  Topomer CoMFA: a design methodology for rapid lead optimization. , 2003, Journal of medicinal chemistry.

[34]  R. Rosenfeld.  Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.